Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI.

Published

Journal Article

BACKGROUND: Coronary revascularization guided by fractional flow reserve (FFR) is associated with better patient outcomes after the procedure than revascularization guided by angiography alone. It is unknown whether the instantaneous wave-free ratio (iFR), an alternative measure that does not require the administration of adenosine, will offer benefits similar to those of FFR. METHODS: We randomly assigned 2492 patients with coronary artery disease, in a 1:1 ratio, to undergo either iFR-guided or FFR-guided coronary revascularization. The primary end point was the 1-year risk of major adverse cardiac events, which were a composite of death from any cause, nonfatal myocardial infarction, or unplanned revascularization. The trial was designed to show the noninferiority of iFR to FFR, with a margin of 3.4 percentage points for the difference in risk. RESULTS: At 1 year, the primary end point had occurred in 78 of 1148 patients (6.8%) in the iFR group and in 83 of 1182 patients (7.0%) in the FFR group (difference in risk, -0.2 percentage points; 95% confidence interval [CI], -2.3 to 1.8; P<0.001 for noninferiority; hazard ratio, 0.95; 95% CI, 0.68 to 1.33; P=0.78). The risk of each component of the primary end point and of death from cardiovascular or noncardiovascular causes did not differ significantly between the groups. The number of patients who had adverse procedural symptoms and clinical signs was significantly lower in the iFR group than in the FFR group (39 patients [3.1%] vs. 385 patients [30.8%], P<0.001), and the median procedural time was significantly shorter (40.5 minutes vs. 45.0 minutes, P=0.001). CONCLUSIONS: Coronary revascularization guided by iFR was noninferior to revascularization guided by FFR with respect to the risk of major adverse cardiac events at 1 year. The rate of adverse procedural signs and symptoms was lower and the procedural time was shorter with iFR than with FFR. (Funded by Philips Volcano; DEFINE-FLAIR ClinicalTrials.gov number, NCT02053038 .).

Full Text

Duke Authors

Cited Authors

  • Davies, JE; Sen, S; Dehbi, H-M; Al-Lamee, R; Petraco, R; Nijjer, SS; Bhindi, R; Lehman, SJ; Walters, D; Sapontis, J; Janssens, L; Vrints, CJ; Khashaba, A; Laine, M; Van Belle, E; Krackhardt, F; Bojara, W; Going, O; Härle, T; Indolfi, C; Niccoli, G; Ribichini, F; Tanaka, N; Yokoi, H; Takashima, H; Kikuta, Y; Erglis, A; Vinhas, H; Canas Silva, P; Baptista, SB; Alghamdi, A; Hellig, F; Koo, B-K; Nam, C-W; Shin, E-S; Doh, J-H; Brugaletta, S; Alegria-Barrero, E; Meuwissen, M; Piek, JJ; van Royen, N; Sezer, M; Di Mario, C; Gerber, RT; Malik, IS; Sharp, ASP; Talwar, S; Tang, K; Samady, H; Altman, J; Seto, AH; Singh, J; Jeremias, A; Matsuo, H; Kharbanda, RK; Patel, MR; Serruys, P; Escaned, J

Published Date

  • May 11, 2017

Published In

Volume / Issue

  • 376 / 19

Start / End Page

  • 1824 - 1834

PubMed ID

  • 28317458

Pubmed Central ID

  • 28317458

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1700445

Language

  • eng

Conference Location

  • United States